Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: HardToFind who wrote (10050)	4/10/2018 6:34:50 AM
From: old 'n cranky	Read Replies (2) \| Respond to of 12873

"I'd give it less than a 10% chance that NNVC will take more than two shingles drug candidates into formal tox testing anytime soon." Without disagreeing with that statement I would point out that in limiting that consideration to shingles drug candidates you may be exercising greater focus than the company itself. "The drug candidates tested in this safety/toxicology study have previously shown broad-spectrum effectiveness against alphaherpesviruses, i.e. HSV-1, HSV-2, and VZV." Keep in mind that this is Slipperyslopeicides, Inc you're dealing with. And you've put your finger on why I made this request in my initial post in response to the PR: "If the answer requires the use of the term "broad spectrum" I hope it includes a further explanation." (Thanks for avoiding it, but you obviously got the point.) "Dr. Diwan seems to be more comfortable keeping his options open and moving forward at this point with multiple herpes drug candidates than selecting a single candidate with which to move forward." Of course he is. Multiple drug candidates and multiple indications extend the process....so far interminably. It is the modus operandi of the company, has been since its inception, and it is the single best way to maximize the costs of development. "The company has heretofore made it known that there were two candidates (specifically referred to in the poster presentation as NV-118 and NV-121)." That poster said lots of stuff, including: "We present here two nanoviricide ® active drug candidates, NV-118 and NV-121, that are highly effective against VZV in vitro:" "NanoViricides, Inc. is now advancing these two drug candidates further into ex vivo dermal and toxicology studies towards IND filing for clinical trials as expeditiously as possible. " "NanoViricides, Inc. is also planning to test these active drug candidates against other human herpesviruses for efficacy and potency and to determine if there is broad-spectrum activity. " Have you ever seen a Phase 1 clinical trial testing a drug candidate for multiple indications at the same time? Do you believe that it is Diwan's intent to move the two shingles candidates forward or to "test these active drug candidates against other human herpesviruses for efficacy and potency and to determine if there is broad-spectrum activity" given the company's historic inability or lack of will to do more than one thing at a time to completion and its current financial condition?